Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)

Trial Profile

A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telotristat etiprate (Primary)
  • Indications Malignant carcinoid syndrome
  • Focus Adverse reactions
  • Acronyms TELEPATH
  • Sponsors Lexicon Pharmaceuticals
  • Most Recent Events

    • 02 Oct 2019 According to a Lexicon Pharmaceuticals media release, data will be presented at he upcoming North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium.
    • 12 Mar 2019 Status changed from active, no longer recruiting to completed.
    • 28 Feb 2019 According to a Lexicon Pharmaceuticals media release, the data from this study will be present at the 16th Annual European Neuroendocrine Tumor Society Conference (Mar 2019).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top